Bayer IR Newsfeed: Events

Bayer IR Newsfeed: Events http://www.investor.bayer.de/ Bayer IR Newsfeed: Investor News Thu, 17 May 2012 14:29:22 +0200 Thu, 17 May 2012 14:29:22 +0200 http://www.investor.bayer.de/ en 1410_2012-0206 <![CDATA[16.05.12: Not intended for U.S. and UK media - 48th Annual Meeting of the American Society of Clinical Oncology (ASCO):]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1410 Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012

First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session

]]> Wed, 16 May 2012 12:00:04 +0200 ir@bayer.com 1408_2012-0212 <![CDATA[09.05.12: Not intended for U.S. and UK media]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1408 Bayer's Xarelto® (Rivaroxaban) Submitted to U.S. FDA to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome

]]> Wed, 9 May 2012 13:00:04 +0200 ir@bayer.com 1406_2012-0188 <![CDATA[02.05.12: Not intended for U.S. and UK media:]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1406 Bayer's Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE

Submissions for marketing authorization supported by the successful global EINSTEIN study program / Rivaroxaban is the first oral single-drug solution proven effective for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)

mehr ...

]]> Wed, 2 May 2012 13:00:04 +0200 ir@bayer.com 1404_2012-0172 <![CDATA[27.04.12: Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders' Meeting of Bayer AG:]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1404 Bayer has great potential for the future too

Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1

mehr ...

]]> Mon, 30 Apr 2012 09:01:07 +0200 ir@bayer.com 1402_2012-6171 <![CDATA[26.04.12: 1st quarter of 2012:]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1402 Encouraging start to the year for Bayer

Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience - increases at HealthCare - continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed

mehr ...

]]> Thu, 26 Apr 2012 05:35:02 +0200 ir@bayer.com 1400_2012-0156 <![CDATA[25.04.12: Not intended for US or UK use - Aesthetic medicine:]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1400 Positive results from two European Phase III trials with ATX-101 demonstrate reduction of submental fat

]]> Wed, 25 Apr 2012 10:30:04 +0200 ir@bayer.com 1398_2012-0180 <![CDATA[20.04.12: New fungicidal seed treatment product for oilseed rape:]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1398 First approval worldwide for EverGol^TM in seed treatment

Launch in Canada planned before the end of the year

]]> Fri, 20 Apr 2012 09:05:03 +0200 ir@bayer.com 1396_2012-0148 <![CDATA[15.04.12: Not intended for U.S. and UK media - Molecular Imaging:]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1396 Bayer sells PET tracers to Piramal

]]> Sun, 15 Apr 2012 20:05:05 +0200 ir@bayer.com 1394_2012-0160 <![CDATA[12.04.12: Not intended for U.S. and UK media]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1394 Bayer's Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE

Submission based on the successful outcome of EINSTEIN-PE study / Rivaroxaban offers the first oral single-drug solution for the initial treatment of PE and long-term prevention of DVT and PE

]]> Thu, 12 Apr 2012 06:30:04 +0200 ir@bayer.com 1392_2012-0006 <![CDATA[11.04.12: Not intended for U.S. and UK media]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1392 Bayer Updates U.S. Labels for Drospirenone-containing Combined Oral Contraceptives

]]> Wed, 11 Apr 2012 06:50:03 +0200 ir@bayer.com 1390_2012-0105 <![CDATA[03.04.12: Not intended for U.S. and U.K. Media]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1390 Phase III Trial of Regorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival

]]> Tue, 3 Apr 2012 06:55:03 +0200 ir@bayer.com 1388_2012-0139 <![CDATA[26.03.12: Not intended for U.S. and UK Media - Treatment of Pulmonary Embolism (PE):]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1388 Bayer's Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study

Rivaroxaban as effective as current standard of care in treatment of pulmonary embolism and secondary prevention of venous blood clots / Patients receiving rivaroxaban showed significantly reduced major bleedings compared to current standard of care / Rivaroxaban offers the first oral single-drug solution for the initial treatment and long-term prevention of pulmonary embolism / Study results presented as a Late-Breaker at the American College of Cardiology Annual Scientific Sessions and published in the New England Journal of Medicine

]]> Mon, 26 Mar 2012 13:05:03 +0200 ir@bayer.com 1386_2012-0119 <![CDATA[19.03.12: Not intended for UK and US Media: Treatment of Pulmonary Embolism (PE):]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1386 Results of the Phase III EINSTEIN-PE Study with Bayer's Xarelto® (Rivaroxaban) to be Presented in Late-Breaking Clinical Trials Session at ACC 2012

]]> Mon, 19 Mar 2012 08:00:04 +0100 ir@bayer.com 1384_2012-0117 <![CDATA[15.03.12: Not intended for U.S. and UK Media]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1384 U.S. FDA approves Natazia^TM as the first combined oral contraceptive to treat heavy menstrual bleeding (HMB)

]]> Thu, 15 Mar 2012 08:35:03 +0100 ir@bayer.com 1382_2012-0118 <![CDATA[14.03.12: "Meet Management" investor conference:]]> http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/1382 Bayer sets ambitious targets for 2014

Good sales and earnings perspectives for HealthCare and CropScience / MaterialScience aims to build on its leading market position

]]> Wed, 14 Mar 2012 06:00:05 +0100 ir@bayer.com